|
|
Reference
|
|
|
*** (2016) Guideline on good pharmacogenomic practice. EMA/CHMP/718998/2016, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacogenomic-practice-first-version_en.pdf
|
|
  
|
Aderhold, K., Wilson, M., Berger, A.C., Levi, S., Bennett, J. (2020) Precision medicine in the treatment of melanoma. Surgical Oncology Clinics of North America, 29(1): 1-13
|
|
|
Atanaskovic, L., Cikota-Aleksic, B., Tarabar, O., Trimcev, J., Zivanovic-Ivic, A., Marjanovic, S., Magic, Z. (2016) Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma. Journal of BUON, 21(6): 1459-1465
|
|
1
|
Collins, F.S., Varmus, H. (2015) A new initiative on precision medicine. New England Journal of Medicine, 372(9): 793-795
|
|
|
Foundation Medicine What is FoundationOne CDx?. https://corpsite.foundationmedicine.com/genomic-testing/foundation-one-cdx
|
|
|
Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., Schnall-Levin, M., White, J., Sanford, E.M., An, P., Sun, J.P., Juhn, F., Brennan, K., Iwanik, K., Maillet, A., Buell, J., White, E. (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 31(11): 1023-1031
|
|
|
Iqbal, N., Iqbal, N. (2014) Imatinib: A breakthrough of targeted therapy in cancer. Chemotherapy Research and Practice, 2014: 1-9, 357027
|
|
|
Kwon, D., Kim, B., Shin, H.C., Kim, E.J., Ha, S.Y., Jang, K., Kim, S.T., Lee, J., Kang, W.K., Park, J.O., Kim, K. (2019) Cancer panel assay for precision oncology clinic: Results from a 1-year study. Translational Oncology, 12(11): 1488-1495
|
|
|
Lamping, M., Benary, M., Leyvraz, S., Messerschmidt, C., Blanc, E., Kessler, T., Schütte, M., Lenze, D., Jöhrens, K., Burock, S., Klinghammer, K., Ochsenreither, S., Sers, C., Schäfer, R., Tinhofer, I. (2020) Support of a molecular tumour board by an evidence-based decision management system for precision oncology. European Journal of Cancer, 127: 41-51
|
|
|
Lee, J., Liu, Z., Sa, J.K., Shin, S., Wang, J., Bordyuh, M., Cho, H.J., Elliott, O., Chu, T., Choi, S.W., Rosenbloom, D.I.S., Lee, I.K., Shin, Y.J., Kang, H.J., Kim, D., Kim, S.Y., Sim, M. (2018) Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, Oct; 50(10): 1399-1411
|
|
|
Li, G., Pavlick, D., Chung, J.H., Bauer, T., Tan, B.A., Peguero, J., Ward, P., Kallab, A., Bufill, J., Hoffman, A., Sadiq, A., Edenfield, J., He, J., Cooke, M., Hughes, J., Forcier, B., Nahas, M., Stephens, P. (2019) Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. Journal of Gastrointestinal Oncology, 10(5): 831-840
|
|
|
Martens, F.K., Huntjens, D.W., Rigter, T., Bartels, M., Bet, P.M., Cornel, M.C. (2020) DPD testing before treatment with fluoropyrimidines in the Amsterdam UMCs: An evaluation of current pharmacogenetic practice. Frontiers in Pharmacology, 10: 1609-1609
|
|
|
National Health Insurance Fund List of medicines. http://rfzo.rs/index.php/osiguranalica/lekovi-info/lekovi-actual
|
|
|
National Library of Medicine What is precision medicine?. https://ghr.nlm.nih.gov/primer/precisionmedicine/definition
|
|
|
Noske, A., Anders, S., Ettl, J., Hapfelmeier, A., Steiger, K., Specht, K., Weichert, W., Kiechle, M., Klein, E. (2020) Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. Breast, 49: 101-107
|
|
|
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., Silvestris, F. (2018) Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 10: 1-24
|
|
|
Penault-Llorca, F., Kwiatkowski, F., Arnaud, A., Levy, C., Leheurteur, M., Uwer, L., Derbel, O., Le, R.A., Jacquin, J., Jouannaud, C.P., Quenel-Tueux, N., Girre, V., Foa, C. (2020) Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14). Breast, 49: 132-140
|
|
1 
|
Rancic, N., Dragojevic-Simic, V., Vavic, N., Kovacevic, A., Segrt, Z., Djordjevic, N. (2016) Economic evaluation of pharmacogenetic tests in patients subjected to renal transplantation: A review of literature. Frontiers in Public Health, 4: 189-189
|
|
1 
|
Rančić, N., Vavić, N., Cikota-Aleksić, B., Magić, Z., Mikov, M., Bokonjić, D., Šegrt, Z., Dragojević-Simić, V. (2018) The relationship between tacrolimus concentration-dose ratio and genetic polymorphism in patients subjected to renal transplantation. Vojnosanitetski pregled, vol. 75, br. 2, str. 147-153
|
|
|
Schrock, A.B., Frampton, G.M., Herndon, D., Greenbowe, J.R., Wang, K., Lipson, D., Yelensky, R., Chalmers, Z.R., Chmielecki, J., Elvin, J.A., Wollner, M., Dvir, A., Gutman, L.S., Bordoni, R., Peled, N., Braiteh, F., Raez, L., Erlich, R., Ou, S.H., Mohamed, M., Ross, J.S. (2016) Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing. Clinical Cancer Research, 22(13): 3281-3285
|
|
|
Suarez-Kurt, G. (2018) Pharmacogenetic testing in oncology: A Brazilian perspective. Clinics, 73(Suppl 1): e565s
|
|
|
Tarabar, O., Cikota-Aleksić, B., Tukić, L., Milanović, N., Aleksić, A., Magić, Z. (2014) Association of interleukin-10, tumor necrosis factor-a and transforming growth factor-b gene polymorphisms with the outcome of diffuse large B-cell lymphomas. International Journal of Clinical Oncology, 19(1): 186-192
|
|
|
U.S. Food and Drug Administration Table of pharmacogenomic biomarkers in drug labeling. Last updated: 12/2019, https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
|
|
4
|
Vavić, N., Rančić, N., Cikota-Aleksić, B., Magić, Z., Cimeša, J., Obrenčević, K., Radojević, M., Mikov, M., Dragojević-Simić, V. (2016) The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation. Vojnosanitetski pregled, vol. 73, br. 7, str. 663-667
|
|
|
Wheeler, H.E., Maitland, M.L., Dolan, M. E., Cox, N.J., Ratain, M.J. (2013) Cancer pharmacogenomics: Strategies and challenges. Nature Reviews Genetics, 14(1): 23-34
|
|
|
Yu, B., O'Toole, S.A., Trent, R.J. (2015) Somatic DNA mutation analysis in targeted therapy of solid tumours. Transl Pediatr, 4(2):125-38
|
|
|
|
|